Algernon Pharmaceuticals Inc. Stock

Equities

AGN

CA01559R4008

Biotechnology & Medical Research

Market Closed - Canadian Securities Exchange 03:59:49 2024-07-19 pm EDT 5-day change 1st Jan Change
0.13 CAD 0.00% Intraday chart for Algernon Pharmaceuticals Inc. 0.00% +100.00%
Sales 2022 - Sales 2023 - Capitalization 2.6M 3.57M
Net income 2022 -6M -8.24M Net income 2023 -6M -8.24M EV / Sales 2022 -
Net cash position 2022 1.41M 1.93M Net cash position 2023 125K 172K EV / Sales 2023 -
P/E ratio 2022
-1.55 x
P/E ratio 2023
-0.37 x
Employees -
Yield 2022 *
-
Yield 2023
-
Free-Float 79.28%
More Fundamentals * Estimated data
Dynamic Chart
Algernon Pharmaceuticals Inc. Reports Results of Study Showing 93% Cough Suppression with Ifenprodil CI
Algernon Pharmaceuticals Inc. announced that it expects to receive CAD 0.25 million in funding CI
Algernon Pharmaceuticals Inc. Reports Earnings Results for the Second Quarter and Six Months Ended February 29, 2024 CI
Algernon Pharmaceuticals Inc. announced that it has received CAD 0.017 million in funding CI
Algernon Pharmaceuticals Inc. announced that it expects to receive CAD 0.017 million in funding CI
Algernon Pharmaceuticals to Move Forward with Psychedelic Drug Dmt Stroke Research Program as Its Lead Asset CI
Algernon Pharmaceuticals Says Acquisition of Ifenprodil Program Completed by US Company MT
Algernon Pharmaceuticals Inc. acquired 20% stake in Seyltx, Inc. CI
Algernon Pharmaceuticals Receives Notice of Intention to Grant from Chinese Patent Office for Repirinast to Treat CKD MT
Algernon Pharmaceuticals Inc. Reports Earnings Results for the First Quarter Ended November 30, 2023 CI
Algernon Pharmaceuticals Inc. Announces Notice of Allowance for Ifenprodil Patent in Japan for Idiopathic Pulmonary Fibrosis CI
Algernon Pharmaceuticals Announces Notice of Allowance for Ifenprodil Patent in Japan for Idiopathic Pulmonary Fibrosis MT
Algernon Pharmaceuticals Inc. Reports Earnings Results for the Full Year Ended August 31, 2023 CI
Algernon Pharmaceuticals Increased Private Placement MT
Algernon Pharmaceuticals Inc. announced that it has received CAD 0.28 million in funding CI
More news
Current month+13.04%
1 month+8.33%
3 months+44.44%
6 months+62.50%
Current year+100.00%
More quotes
1 week
0.13
Extreme 0.125
0.14
1 month
0.11
Extreme 0.11
0.14
Current year
0.07
Extreme 0.07
0.17
1 year
0.05
Extreme 0.05
0.22
3 years
0.05
Extreme 0.05
3.25
5 years
0.05
Extreme 0.05
14.50
10 years
0.05
Extreme 0.05
27.50
More quotes
Managers TitleAgeSince
Chief Executive Officer 59 18-02-28
Director of Finance/CFO 46 21-11-30
Chief Operating Officer 41 21-02-28
Members of the board TitleAgeSince
Chairman 79 21-09-07
Chief Executive Officer 59 18-02-28
Director/Board Member 52 21-09-21
More insiders
Date Price Change Volume
24-07-19 0.13 0.00% 6,500
24-07-18 0.13 0.00% 6,000
24-07-17 0.13 0.00% 29,020
24-07-16 0.13 0.00% 58,000
24-07-15 0.13 0.00% 40,500

Delayed Quote Canadian Securities Exchange, July 19, 2024 at 03:59 pm EDT

More quotes
Algernon Pharmaceuticals Inc. is a clinical-stage drug development company. The Company is focused on developing repurposed therapeutic drugs in the areas of non-alcoholic steatohepatitis (NASH), a type of liver disease, chronic kidney disease (CKD), inflammatory bowel disease (IBD), idiopathic pulmonary fibrosis (IPF) and chronic cough as well as advancing a stroke program using N, N-Dimethyltryptamine (DMT). The Company operates through two segments, which includes the development of repurposed therapeutic drugs in Canada and the facilitation of the Company’s lead drug candidates into off-label phase II clinical trials (humans) in Australia. The Company's pipeline includes NP-251 (Repirinast) and AP-188 (DMT). The Company, through its subsidiary, Algernon NeuroScience Inc., is developing AP-188 (DMT) as a potential treatment for stroke and traumatic brain injury (TBI) recovery. Its NP-251 is being developed as a potential treatment for kidney inflammation and fibrosis.
More about the company

Quarterly revenue - Rate of surprise